HUMAN IMMUNOLOGIC MONITORING
HUMAN IMMUNOLOGIC MONITORING
批准号:
7714284
负责人:
THOMAS F GAJEWSKI
金额:
$8.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-22 至 2013-03-31
关键词:
Allogeneic Bone Marrow TransplantationAreaBindingBiological AssayBiological MonitoringCD8B1 geneCancer PatientCancer VaccinesCellsClinicalClinical TrialsCyclic GMPEffectivenessEnd PointFailureGraft-Versus-Tumor InductionHeartHematopoieticHumanImmuneImmune responseImmunologic MonitoringImmunologicsImmunotherapeutic agentInterferonsInterleukin-2InterventionInvestigationInvestigational TherapiesLaboratoriesLymphocyteLymphomaMalignant NeoplasmsMalignant neoplasm of kidneyMeasuresMediatingMonitorMonoclonal AntibodiesPatientsPharmacodynamicsPreparationPurposeRangeRenal carcinomaResearch PersonnelRoche brand of rituximabRoche brand of trastuzumabServicesSignal Transduction InhibitorSpecificityStudy SubjectT-LymphocyteTherapeutic EffectTimeTissuesTreatment EfficacyTumor AntigensUnited States Food and Drug AdministrationUniversity of Chicago Cancer Research Centercancer immunotherapycytokineimprovedmalignant breast neoplasmmelanomanovelresponsesuccesstumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The specific recognition of tumor antigens by CD8+ T cells, and the binding of monoclonal antibodies to
tumor targets represent the main effector mechanisms for immune-mediated tumor rejection. The
exquisite specificity of these interactions has earned cancer immunotherapy the designation as a
targeted therapy. Excitement in this area was reinforced by the FDA approval of several monoclonal
antibodies, such as Herceptin for breast cancer and Rituxan for lymphoma, as well as two cytokines,
interleukin-2 and interferon-a, for the treatment of melanoma and kidney cancer. In addition, allogeneic
bone marrow transplantation has therapeutic effects through a cell-mediated graft-versus-tumor
immune response. However, the efficacy of these therapies is still suboptimal. Improving upon the
effectiveness of current agents, developing new immunotherapeutic interventions (such as anti-cancer
vaccines), and elucidating the mechanism of success versus failure of investigational treatments, all
require careful monitoring of scientific endpoints.
The main purpose of the Human Immunologic Monitoring Facility is to perform such assays in the
context of clinical trials in cancer patients. As such, it serves as a specialized laboratory for evaluating
pharmacodynamic parameters in response to agents or interventions that impact on immune cells. This
service enables a range of clinical cancer researchers, who don't necessarily have laboratory expertise
themselves, to measure immunologic endpoints in participating study subjects. The Facility also
monitors biologic effects of other pharmacologic agents (such as signal transduction inhibitors) using
lymphocytes or other hematopoietic cells as a surrogate tissue. Finally, the technologists of our Core
interface with the cGMP Facility to carry out the preparation of clinical-grade products, such as cancer
vaccines, for administration to patients. Thus, this Facility lies at the heart of our clinical/translational
effort in cancer immunotherapy, and is vital for the scientific investigation of additional novel agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10057358
-
项目类别:
-
资助金额:$94.33万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10547757
-
项目类别:
-
资助金额:$92.71万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10737852
-
项目类别:
-
资助金额:$97.02万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:9186858
-
项目类别:
-
资助金额:$94.12万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10304876
-
项目类别:
-
资助金额:$92.46万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Host STING pathway in anti-tumor immunity
-
批准号:8759184
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2014
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8370154
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:9066116
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8914542
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8677803
-
项目类别:
-
资助金额:$31.8万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
PROGRAM 3 (IMMUNOLOGY AND CANCER)
-
批准号:8518668
-
项目类别:
-
资助金额:$14.0万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8518271
-
项目类别:
-
资助金额:$30.82万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
DGK in T Cell Regulation and Tolerance
-
批准号:7896647
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2009
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
DGK in T Cell Regulation and Tolerance
-
批准号:7740296
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2009
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Deletion of inhibitory genes in post-thymic T cells to study immune tolerance
-
批准号:7510004
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2008
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Deletion of inhibitory genes in post-thymic T cells to study immune tolerance
-
批准号:7646453
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2008
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
PROGRAM 3 (IMMUNOLOGY AND CANCER)
-
批准号:7714255
-
项目类别:
-
资助金额:$1.56万
-
财政年份:2008
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Countering immune resistance in the melanoma tumor microenvironment
-
批准号:8019440
-
项目类别:
-
资助金额:$27.47万
-
财政年份:2007
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Countering immune resistance in the melanoma tumor microenvironment
-
批准号:7248282
-
项目类别:
-
资助金额:$29.17万
-
财政年份:2007
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Countering immune resistance in the melanoma tumor microenvironment
-
批准号:7564792
-
项目类别:
-
资助金额:$29.17万
-
财政年份:2007
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: